 |
| Carin Canale-Theakston |
Dublin-based UDG Healthcare has acquired San Diego’s Canale Communications, the life sciences PR firm that has served more than 300 biotech, medical devices, digital health, and pharmaceutical companies since its launch in 2010.
UDG, which employs 8,500 people in 26 countries, is the parent of Ashford Healthcare Communications, provider of advisory, communication, commercial and clinical services for the pharmaceutical and healthcare industries.
CanaleComm, which will retain its name, will become part of AHC.
CEO Carin Canale-Theakston, former head of Porter Novelli’s life sciences unit and partner of boutique shop Atkins + Assocs. that was acquired by PN, called AHC “the ideal platform" as the firm looks to grow a more robust service offering. “UDG Healthcare’s focus on life sciences, complementary offering, and strong employee-first culture were all extremely attractive to CanaleComm,” she said.
Matt Jacobson, AHC executive director, views the deal as a way to strengthen his firm’s US footprint, expecially in the west coast biotech sector.
CanaleComm, which has 30 staffers, has worked with Johnson & Johnson, Avidity Biosciences, Genome Medical, The Cleary Foundation, Dauntless Pharmaceutical and Cirius Therapeutics.
WPP reported a 5.5 percent decline in Q1 PR revenues to $292M as its BCW and Hill & Knowlton units suffered the loss of Pfizer assignments, and cutbacks in client spending due to the economic uncertainty.
Interpublic CEO Philippe Krakowsky said the firm is off to a “solid start to the year” as its flat $2.2B net revenues are in line with 2024 financial targets.
Why financial planning always plays a crucial role in every PR firm’s success.
Omnicom CEO John Wren reports Q1 revenues jumped 5.4 percent to $3.6M, powered by a solid 7.0 percent rise in its advertising & media segment.
Public Policy Holding Company registered 24.1 percent growth to a record $135M during the past year, which included the results of the March 1 acquisition of Multistate Assocs.
Have a comment? Send it to 
No comments have been submitted for this story yet.